Portal de Periódicos da CAPES

Bisphosphonates associated osteonecrosis of the jaw: A long‐term follow‐up of a series of 35 cases observed by GISL and evaluation of its frequency over time

2009; Wiley; Volume: 84; Issue: 12 Linguagem: Francês

10.1002/ajh.21553

1096-8652

Samantha Pozzi, Raffaella Marcheselli, Simona Falorio, Luciano Masini, Caterina Stelitano, Antonietta Falcone, Giovanni Quarta, Luisa Ponchio, Vincenzo Pitini, Stefano Luminari, Luca Baldini,

Cancer Diagnosis and Treatment

American Journal of HematologyVolume 84, Issue 12 p. 850-852 LettersFree Access Bisphosphonates associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time† Samantha Pozzi, Corresponding Author Samantha Pozzi [email protected] Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, ItalyDepartment of Oncology and Hematology, Centro Oncologico Modenese, University of Modena, Modena 41100, ItalySearch for more papers by this authorRaffaella Marcheselli, Raffaella Marcheselli Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, ItalySearch for more papers by this authorSimona Falorio, Simona Falorio Dipartimento di Ematologia, USL di Pescara, Centro Diagnosi e Cura dei Linfomi, Ospedale Santo Spirito, Pescara, ItalySearch for more papers by this authorLuciano Masini, Luciano Masini Ospedale "Santa Maria Nuova," Reggio Emilia, ItalySearch for more papers by this authorCaterina Stelitano, Caterina Stelitano Divisione di Ematologia, Pres. Osp. Riuniti—"Bianchi, Melacrino, Morelli," Reggio Calabria, ItalySearch for more papers by this authorAntonietta Falcone, Antonietta Falcone IRCCS "Casa Sollievo della Sofferenza," San Giovanni Rotondo, ItalySearch for more papers by this authorGiovanni Quarta, Giovanni Quarta Divisione di Ematologia, Osp. A. Perrino, Brindisi, ItalySearch for more papers by this authorLuisa Ponchio, Luisa Ponchio Sezione di Oncologia Medica I, Istituto Scientifico Fondazione S. Maugeri, Pavia, ItalySearch for more papers by this authorVincenzo Pitini, Vincenzo Pitini Dipartimento di Oncologia, Università di Messina, Messina, ItalySearch for more papers by this authorStefano Luminari, Stefano Luminari Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, ItalySearch for more papers by this authorLuca Baldini, Luca Baldini UO Ematologia 1/CTMO, Ospedale Maggiore Policlinico MaRe, IRCCS, Università degli Studi, Milan, ItalySearch for more papers by this author Samantha Pozzi, Corresponding Author Samantha Pozzi [email protected] Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, ItalyDepartment of Oncology and Hematology, Centro Oncologico Modenese, University of Modena, Modena 41100, ItalySearch for more papers by this authorRaffaella Marcheselli, Raffaella Marcheselli Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, ItalySearch for more papers by this authorSimona Falorio, Simona Falorio Dipartimento di Ematologia, USL di Pescara, Centro Diagnosi e Cura dei Linfomi, Ospedale Santo Spirito, Pescara, ItalySearch for more papers by this authorLuciano Masini, Luciano Masini Ospedale "Santa Maria Nuova," Reggio Emilia, ItalySearch for more papers by this authorCaterina Stelitano, Caterina Stelitano Divisione di Ematologia, Pres. Osp. Riuniti—"Bianchi, Melacrino, Morelli," Reggio Calabria, ItalySearch for more papers by this authorAntonietta Falcone, Antonietta Falcone IRCCS "Casa Sollievo della Sofferenza," San Giovanni Rotondo, ItalySearch for more papers by this authorGiovanni Quarta, Giovanni Quarta Divisione di Ematologia, Osp. A. Perrino, Brindisi, ItalySearch for more papers by this authorLuisa Ponchio, Luisa Ponchio Sezione di Oncologia Medica I, Istituto Scientifico Fondazione S. Maugeri, Pavia, ItalySearch for more papers by this authorVincenzo Pitini, Vincenzo Pitini Dipartimento di Oncologia, Università di Messina, Messina, ItalySearch for more papers by this authorStefano Luminari, Stefano Luminari Centro Oncologico Modenese, Policlinico di Modena, Università di Modena e, Reggio Emilia, ItalySearch for more papers by this authorLuca Baldini, Luca Baldini UO Ematologia 1/CTMO, Ospedale Maggiore Policlinico MaRe, IRCCS, Università degli Studi, Milan, ItalySearch for more papers by this author First published: 29 September 2009 https://doi.org/10.1002/ajh.21553Citations: 9 † Conflict of Interest: Nothing to report. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1117. 2 Ruggiero SL,Mehrotra B,Rosenberg TJ,Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62(5): 527–534. 3 Pozzi S,Marcheselli R,Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48: 56–64. 4 Khosla S,Burr D,Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American society for bone and mineral research. J Bone Miner Res 2007; 22: 1479–1491. 5 Badros A,Evangelos T,Goloubeva O, et al. Long-term follow-up of multiple myeloma (MM) patients (pts) with osteonecrosis of the jaw (ONJ). American Society of Hematology. Blood 2007; 110: 3519. 6 Mehrotra B,Fantasia J,Ruggiero S. Outcomes of bisphosphonate-related osteonecrosis of the jaw-importance of staging and management guidelines: A large single institution update. American Society of Clinical Oncology. J Clin Oncol 2008; 20526. 7 Wang EP,Kaban LB,Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65: 1328–1331. 8 Hoff AO,Toth BB,Altundag K, et al. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826–836. 9 Dimopoulos MA,Kastritis E,Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117–120. Citing Literature Volume84, Issue12December 2009Pages 850-852 ReferencesRelatedInformation